Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone Acetonide Dose Comparison in Knee Osteoarthritis
NCT05806021Phase 4Recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of triamcinolone acetonide in knee osteoarthritis (OA) (3 arms), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index Function Subscale at 1 month. Started Jan 2024; status: recruiting.
02
Drugs
triamcinolone acetonide
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05806021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806021.